melanoma

[npj Precision Oncology] In a TCGA-melanoma dataset, tumor cellularity exhibited additive prognostic value in the immune score signature to predict overall survival in patients with early-stage melanoma.

[Clinical Cancer Research] Researchers used mass cytometry by time-of-flight, flow cytometry, and T cell receptor immunosequencing to conduct simultaneous single-cell analyses of immune cells in the sentinel lymph nodes of melanoma patients.

[Xilio Therapeutics, Inc.] Xilio Therapeutics, Inc. announced that the first patient has been dosed in the company’s Phase I/II clinical trial evaluating XTX202 for the treatment of solid tumors. XTX202 is a modified form of IL-2 that is designed to localize activity in the tumor microenvironment.

[Cancer Gene Therapy] Investigators overexpressed MYC in freshly isolated human primary melanocytes and studied the effects on melanocytic proliferation and differentiation.

[Communications Biology] Viscoelastic measurements revealed that 2D adherent metastatic melanoma cells exhibit reduced elasticity compared to their normal counterparts—melanocytes and fibroblasts.

[Cell Death & Disease] The authors showed 2nd generation hexameric TRAIL-receptor-agonist IZI1551 to effectively induce apoptosis in malignant melanoma cells irrespective of the intrinsic BRAF/NRAS mutation status.